Advertisement

Topics

MeMed Ltd. Company Profile

02:10 EST 12th December 2018 | BioPortfolio

MeMed is dedicated to improving patient lives through research, development and commercialization of pioneering products that decode the immune system's distinct responses to different health and disease states. The company focuses on providing rapid, accurate and actionable diagnostic solutions for acute infectious diseases and inflammatory disorders in the hospital and community. The company’s most advanced product, ImmunoXpertTM, accurately and rapidly detects if a patient has a bacterial or viral infection, with the aim of empowering physicians to make better informed antibiotic treatment decisions. ImmunoXpertTM is CE marked and approved for clinical use in the EU, Switzerland and Israel, with pilot distribution efforts underway. For additional information, please visit www.me-med.com.


News Articles [7 Associated News Articles listed on BioPortfolio]

Ping An Leads $70 Million Round in MeMed, an Israeli Diagnostics Company

Ping An Global Voyager Fund invested $20 million in Israeli diagnostic company MeMed as part of MeMed's $70 million C round. MeMed has developed MeMed BV, a blood test that distinguishes between bacte...

Israeli diagnostics firm MeMed raises over $70m funding

MeMed has secured the funding from new and existing investors including Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WT...

MeMed brings in $70mm via Series C

In what appears to be a Series C financing, diagnostics firm MeMed raised over $70mm from new and returning backers including Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insu...

MeMed raises over $70M

MeMed raises $70M in funding round

A round of financing involving Ping An Global Voyager Fund and other investors has pulled in more than $70 million for Haifa, -More- 

Israeli diagnostics co MeMed raises $70m

The Haifa-based company has developed an immune-system based test for distinguishing between bacterial and viral infections.

Week in Review: WuXi AppTec Files for $1 Billion+ Hong Kong IPO at $13 Billion Valuation

Deals and Financings WuXi AppTec filed for a Hong Kong IPO that will raise at least $1 billion and value the company at $13 billion, four months after it completed a $354 million IPO in Shanghai; Hil...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

MeMed Ltd.

MeMed is dedicated to improving patient lives through research, development and commercialization of pioneering products that decode the immune system's distinct responses to diff...

More Information about "MeMed Ltd." on BioPortfolio

We have published hundreds of MeMed Ltd. news stories on BioPortfolio along with dozens of MeMed Ltd. Clinical Trials and PubMed Articles about MeMed Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MeMed Ltd. Companies in our database. You can also find out about relevant MeMed Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record